Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report released on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.

A number of other equities research analysts have also commented on the stock. HC Wainwright reaffirmed a buy rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research note on Friday, June 14th. Canaccord Genuity Group decreased their price target on Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a report on Thursday, May 16th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $14.80.

Aptose Biosciences Stock Down 7.5 %

Shares of NASDAQ:APTO opened at $0.51 on Friday. The business has a fifty day simple moving average of $0.72 and a 200 day simple moving average of $1.25. Aptose Biosciences has a 12-month low of $0.40 and a 12-month high of $5.10. The firm has a market cap of $9.29 million, a P/E ratio of -0.08 and a beta of 1.27.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.15. As a group, equities research analysts expect that Aptose Biosciences will post -2.62 EPS for the current year.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.